In Silico Clinical Trials Market To Reach $5.59 Billion By 2030

In Silico Clinical Trials Market Growth & Trends

The global in silico clinical trials market size is anticipated to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.74% from 2025 to 2030. Traditional clinical trials require huge expenditure to conduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing to the lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silico clinical trials, to understand the behavior of drugs or medical devices in humans. In silico clinical trials use simulation techniques to understand the efficacy and safety of a drug or medical device.

This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments to provide new treatments to the people. For instance, in June 2021, In silico Medicine raised USD 255 million in funding to boost its R&D for drug discovery, through in silico studies. The demand for in silico clinical trials was also improved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silico research models. Such actions are likely to have a positive impact on market growth.

 Request a free sample copy or view report summary: In Silico Clinical Trials Market Report

In Silico Clinical Trials Market Report Highlights

• The medical device segment dominated the market in 2024 owing to the fact that the majority of in silico trials are performed for medical devices globally

• The phase II segment accounted for the largest market revenue share in 2024

• The oncology therapeutic area segment accounted for the largest market revenue share in 2024

• The cancer clinical trials have high chances of incurring adverse effects on patients, which promotes the demand for in silico trials for cancer

• North America held the largest revenue share in 2024 due to the presence of several global players operating in the market

• In addition, a significant number of in silico trials are performed in the U.S., which further contributes to the growth of the regional market

In Silico Clinical Trials Market Segmentation

Grand View Research has segmented the global in silico clinical trials market report on the basis of industry, therapeutic area, phase and region:

In Silico Clinical Trials Industry Outlook (Revenue, USD Million, 2018 - 2030)

• Medical Devices

• Pharmaceutical

In Silico Clinical Trials Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Infectious Disease

• Hematology

• Cardiology

• Dermatology

• Neurology

• Diabetes

• Others

In Silico Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

In Silico Clinical Trials Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players in the In Silico Clinical Trials Market

• Certara, Inc.

• Novadiscovery Sas

• Insilico Medicine, Inc.

• Dassault Systemes SE

• GNS Healthcare Inc.

• The AnyLogic Company

• InSilicoTrials

• Immunetrics Inc.

• Nuventra Pharma Sciences

• Abzena Ltd.